Skip to Content
  • Previous Rank19
  • Revenue 3 Yr Annual Growth Rate31%
  • Revenue 3 Yr Growth Rank39
  • EPS 3 Yr Annual Growth Rate273%
  • EPS 3 Yr Growth Rank1
  • Total Return 3 Yr Annual Rate47%
  • Total Return 3 Yr Rank
    15

This biotech licensor’s two hit drugs–Krypolis, used to treat blood cancer, and Promacta, used to prevent bleeding episodes–injected big royalties last year.

Fortune Data StoreLooking for leads, investment insights, or competitive intelligence?Get Premium Access

Company Information

Location
San Diego, Calif.
Industry
Pharmaceuticals
Sector
Health Care
Current Streak3
Years on List3
CEO
John Higgins
Websitehttp://www.ligand.com
Includes a $220 million income benefit relating to the company's deferred tax assets.!Revenue and net income for the four quarters ended on or before April 30, 2016.!Total return for the period ended June 30, 2016.

Revenue, Net Income

Revenue Past Four Quarters ($M)$87
Net Income Past Four Quarters ($M)$263

Growth Rates and Ranks

Revenue 3 Yr Growth Rank39
EPS 3 Yr Annual Growth Rate273%
EPS 3 Yr Growth Rank1
Total Return 3 Yr Annual Rate47%
Total Return 3 Yr Rank
15